Pathogenesis and New Treatments for Primary Ciliary Dyskinesia (PCD)
Official title: Pathogenesis and Therapeutic Approaches in Primary Ciliary Dyskinesia
Funded at University of Iowa · NIH-11353875 · Data updated 2026-11-12
Researchers are studying why Primary Ciliary Dyskinesia causes lung and airway problems and how to develop better treatments for people with this condition.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | June 15, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,302,228 |
| NIH project number | 5P01HL172740-02 |
| Project ID | NIH-11353875 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Primary Ciliary Dyskinesia or related ciliary disorders, and families participating in genetic and phenotype studies.
✕Less likely to help
Patients without PCD or without access to specialized centers may not directly benefit from this research.
What this research studies
This project uses a pig model with a disrupted DNAI1 gene to mimic human PCD and study how faulty cilia lead to airway disease from birth through adulthood. It aims to uncover early disease pathways, how mitochondrial metabolism changes when cilia don’t beat properly, and whether the DNAI1 gene itself can be targeted for therapy. By linking genetic cause to cellular changes and clinical symptoms, the work seeks to identify promising treatment strategies that could improve breathing and reduce infections for patients with PCD. The program builds on prior findings about cilia structure and function and plans integrated studies across biology and physiology to translate discoveries into real patient benefits.
Why it matters
Potential benefit: If successful, the research could reveal new targets and strategies to prevent or treat airway damage in people with PCD.
How similar studies have gone: Previous research using animal models and genetic approaches has advanced understanding of PCD, and this project aims to translate those insights into therapies.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Stoltz, David a — University of Iowa
- Study coordinator: Stoltz, David a
Related research
Other NIH-funded projects on the same topics.
-
Personalized therapeutic oligonucleotides for primary ciliary dyskinesia
A new therapy approach uses customized RNA-based medicines to help people with Primary Ciliary Dyskinesia, a rare lung condition, by correcting how genes are read in airway cells.
-
New genes behind primary ciliary dyskinesia
This project looks for new genes that cause primary ciliary dyskinesia to help people with chronic respiratory infections and related complications.
-
How a lung cell protein (cytoglobin) affects cilia movement and organ placement
Researchers are looking at whether the airway protein cytoglobin controls nitric oxide and cilia motion in ways that could explain primary ciliary dyskinesia and situs inversus.
-
Understanding and treating Primary Ciliary Dyskinesia
This study is looking at a pig model of Primary Ciliary Dyskinesia (PCD) to better understand how the condition affects breathing and to find new ways to help improve the lives of people living with PCD.
-
Finding new genes that cause primary ciliary dyskinesia
This study is looking for new genes that cause primary ciliary dyskinesia (PCD), a condition that affects breathing, to help make faster and cheaper tests for it, using a special model from frog embryos to learn more about how cilia work.
-
Understanding how a protein affects cilia movement and organ development in airway diseases.
This study is looking at how a protein called cytoglobin helps tiny hair-like structures in your airways work properly, which is important for people with primary ciliary dyskinesia (PCD) and related breathing problems, with the hope of finding better ways to diagnose and treat these conditions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.